ODA
0.115
167.4%
JDO
0.915
-40.4%
AOK
0.003
50%
FBR
0.002
-33.3%
NX1
0.018
38.5%
MFD
0.16
-33.3%
T3D
0.046
31.4%
UM1
0.1
-31%
EIQ
1.615
30.2%
M2M
0.007
-30%
DXN
0.23
27.8%
CLU
0.005
-28.6%
BSR
0.465
27.4%
ALY
0.006
-25%
DME
0.04
25%
BLU
0.003
-25%
FCT
0.01
25%
CAN
0.003
-25%
NPM
0.016
23.1%
CCR
0.15
-25%
CLA
0.006
20%
NMT
0.021
-25%
OEL
0.006
20%
TON
0.003
-25%
OSM
0.62
17%
TSK
0.065
-23.5%
MEM
0.007
16.7%
AM3
0.004
-20%
PET
0.007
16.7%
IBX
0.012
-20%
SKM
0.25
16.3%
T88
0.04
-20%
SFX
0.041
13.9%
DTM
0.013
-18.8%
PTX
0.066
13.8%
AUV
0.009
-18.2%
3PL
0.335
13.6%
INF
0.009
-18.2%
CXL
0.475
13.1%
KNG
0.045
-18.2%
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

CMH Clinical trial openfor enrollment

Chimeric Therapeutics (ASX:CHM), Australian leader in cell therapy, announces the Phase 18 ADVENT-AML clinical trial for patients with newly diagnosed Acute Myeloid Leukaemia is now open to enrolment at The University of Texas MD Anderson Cancer Center https://cdn-api.markitdigital.com/apiman-gateway/ASX/asx-research/1.0/file/2924-02762504-2A1499759